Preferential inhibition of human phosphodiesterase 4 by ibudilast

Life Sciences

Volumn 78, Issue 23, 2006, Pages 2663-2668

  Huang, Zheng ^a   Liu, Susana ^a   Zhang, Lei ^a   Salem, Myriam ^a   Greig, Gillian M ^a   Chi Chung Chan, ^a   Natsumeda, Yutaka ^b   Noguchi, Kazuhito ^b  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Allergic conjunctivitis; Ibudilast; KC 404; LTB4; PDE4; Phosphodiesterase; TNF

Indexed keywords

ANTIALLERGIC AGENT; ANTIINFLAMMATORY AGENT; CILOMILAST; CROMOGLYCATE DISODIUM; EYE DROPS; EYEVINAL; FORMYLMETHIONYLLEUCYLPHENYLALANINE; IBUDILAST; KETOTIFEN; LEUKOTRIENE B4; LEVOCABASTINE; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE 3A; PHOSPHODIESTERASE 3B; PHOSPHODIESTERASE 4A; PHOSPHODIESTERASE 4B; PHOSPHODIESTERASE 4C; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE 5A; PHOSPHODIESTERASE 7A; PHOSPHODIESTERASE 7B; PHOSPHODIESTERASE 9A; PHOSPHODIESTERASE I; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; RECOMBINANT ENZYME; RIBOSUTIN; ROLIPRAM; TRANILAST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZAJIDEN;

ANIMAL CELL; ANTIALLERGIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; EYE ALLERGY; HUMAN; IC 50; NONHUMAN;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AMIDES; ANIMALS; CELL LINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKOTRIENE B4; LIPOPOLYSACCHARIDES; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; PHOSPHODIESTERASE INHIBITORS; PYRIDINES; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 33646020377     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.10.026     Document Type: Article

References (41)

1. Armstead W.M., Mirro R., Leffler C.W., and Busija D.W. The role of prostanoids in the mediation of responses to KC-404, a novel cerebrovasodilator. Journal of Pharmacology and Experimental Therapeutics 244 (1988) 138-143
2. Banner K.H., Roberts N.M., and Page C.P. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. British Journal of Pharmacology 116 (1995) 3169-3174
3. Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. Journal of Allergy and Clinical Immunology 106 (2000) 1019-1032
4. Brideau C., Van Staden C., Styhler A., Rodger I.W., and Chan C.C. The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay. British Journal of Pharmacology 126 (1999) 979-988
5. Claveau D., Chen S.L., O'Keefe S., Zaller D.M., Styhler A., Liu S., Huang Z., Nicholson D.W., and Mancini J.A. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141, a potent and selective phosphodiesterase 4 inhibitor. Journal of Pharmacology and Experimental Therapeutics 310 (2004) 752-760
6. Conti M., Richter W., Mehats C., Livera G., Park J.Y., and Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. Journal of Biological Chemistry 278 (2003) 5493-5496
7. Crocker I.C., Ohia S.E., Church M.K., and Townley R.G. Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors. Journal of Allergy and Clinical Immunology 102 (1998) 797-804
8. Denis D., and Riendeau D. Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes. European Journal of Pharmacology 367 (1999) 343-350
9. Feng J., Misu T., Fujihara K., Sakoda S., Nakatsuji Y., Fukaura H., Kikuchi S., Tashiro K., Suzumura A., Ishii N., Sugamura K., Nakashima I., and Itoyama Y. Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Multiple Sclerosis 10 (2004) 494-498
10. Flamand N., Surette M.E., Picard S., Bourgoin S., and Borgeat P. Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Molecular Pharmacology 62 (2002) 250-256
11. Gamble E., Grootendorst D.C., Brightling C.E., Troy S., Qiu Y., Zhu J., Parker D., Matin D., Majumdar S., Vignola A.M., Kroegel C., Morell F., Hansel T.T., Rennard S.I., Compton C., Amit O., Tat T., Edelson J., Pavord I.D., Rabe K.F., Barnes N.C., and Jeffrey P.K. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 168 (2003) 976-982
12. Gantner F., Tenor H., Gekeler V., Schudt C., Wendel A., and Hatzelmann A. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. Journal of Allergy and Clinical Immunology 100 (1997) 527-535
13. Giembycz M.A. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Current Opinion in Pharmacology 5 (2005) 238-244
14. Houslay M.D., and Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends in Biochemical Sciences 22 (1997) 217-224
15. Huang Z., Ducharme Y., Macdonald D., and Robichaud A. The next generation of PDE4 inhibitors. Current Opinion in Chemical Biology 5 (2001) 432-438
16. Kawasaki A., Hoshino K., Osaki R., Mizushima Y., and Yano S. Effect of ibudilast: a novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma. Journal of Asthma 29 (1992) 245-252
17. Kishi Y., Ohta S., Kasuya N., Sakita S., Ashikaga T., and Isobe M. Ibudilast: a non-selective pde inhibitor with multiple actions on blood cells and the vascular wall. Cardiovascular Drug Reviews 19 (2001) 215-225
18. Kitano S., Kogure F., Miyanaga Y., Ohno S., Mikuni I., Yuasa T., Mochizuki M., and Nakashima M. Clinical evaluation of KC-404 ophthalmic solution in the treatment of allergic conjunctivitis (including pollinosis) and vernal conjunctivitis: a comparative study with disodium cromoglycate ophthalmic solution. Journal of Eye 16 (1999) 1449-1465
19. Kudo Y., Sugiura H., Ohashi M., and Nishino K. Influence of indomethacin on an increase in cerebral blood flow induced by KC-404, a novel cerebral vasodilator, in an anesthetized dog. General Pharmacology 17 (1986) 339-341
20. Laliberte F., Han Y., Govindarajan A., Giroux A., Liu S., Bobechko B., Lario P., Bartlett A., Gorseth E., Gresser M., and Huang Z. Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry 39 (2000) 6449-6458
21. Laliberte F., Liu S., Gorseth E., Bobechko B., Bartlett A., Lario P., Gresser M.J., and Huang Z. In vitro PKA phosphorylation-mediated human PDE4A4 activation. FEBS Letters 512 (2002) 205-208
22. Lipworth B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365 (2005) 167-175
23. Liu S., Laliberte F., Bobechko B., Bartlett A., Lario P., Gorseth E., Hamme J.V., Gresser M., and Huang Z. Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry 40 (2001) 10179-10186
24. Liu S., Veilleux A., Zhang L., Young A., Kwok E., Laliberte F., Chung C., Tota M.R., Dube D., Friesen R.W., and Huang Z. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. Journal of Pharmacology and Experimental Therapeutics 314 (2005) 846-854
25. McGill J. Conjunctival cytokines in ocular allergy. Clinical & Experimental Allergy 30 (2000) 1355-1357
26. Meliton A.Y., Munoz N.M., Liu J., Lambertino A.T., Boetticher E., Myo S., Myou S., Zhu X., Johnson M., and Leff A.R. Blockade of LTC4 synthesis caused by additive inhibition of gIV-PLA2 phosphorylation: effect of salmeterol and PDE4 inhibition in human eosinophils. Journal of Allergy and Clinical Immunology 112 (2003) 404-410
27. Mizuno T., Kurotani T., Komatsu Y., Kawanokuchi J., Kato H., Mitsuma N., and Suzumura A. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 46 (2004) 404-411
28. Nishino K., Ohkubo H., Ohashi M., Hara S., Kito J., and Irikura T. KC-404: a potential anti-allergic agent with antagonistic action against slow reacting substance of anaphylaxis. Japanese Journal of Pharmacology 33 (1983) 267-278
29. Niwa M., Kohno K., al Essa L.Y., Kobayashi M., Nozaki M., and Tsurumi K. Ibudilast, an anti-allergic and cerebral vasodilator, modulates superoxide production in human neutrophils. Life Sciences 56 (1995) 107-115
30. Noguchi K., Kobayashi K., Nishikibe M., and Ikemeto F. Preventive effect of ophthalmic ibudilast on experimental allergic conjunctivitis in the guinea pig. Journal of Eye 11 (1994) 1747-1754
31. Ohashi M., Kanai R., Nishino K., Sato T., and Takayanagi I. Antagonistic effect of KC-404, a new anti-asthmatic agent, on leukotriene D4-induced contractile responses in isolated guinea pig smooth muscles. Prostaglandins 32 (1986) 875-888
32. Ohashi M., Ohkubo H., Kito J., and Nishino K. A new vasodilator 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine (KC-404) has a dual mechanism of action on platelet aggregation. Archives Internationales de Pharmacodynamie et de Thérapie 283 (1986) 321-334
33. Profita M., Chiappara G., Mirabella F., Di Giorgi R., Chimenti L., Costanzo G., Riccobono L., Bellia V., Bousquet J., and Vignola A.M. Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 58 (2003) 573-579
34. Robichaud A., Stamatiou P.B., Jin S.L., Lachance N., Macdonald D., Laliberte F., Liu S., Huang Z., Conti M., and Chan C.C. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. Journal of Clinical Investigation 110 (2002) 1045-1052
35. Scapin G., Patel S.B., Chung C., Varnerin J.P., Edmondson S.D., Mastracchio A., Parmee E.R., Singh S.B., Becker J.W., Van der Ploeg L.H., and Tota M.R. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity. Biochemistry 43 (2004) 6091-6100
36. Sette C., and Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. Journal of Biological Chemistry 271 (1996) 16526-16534
37. Souness J.E., Villamil M.E., Scott L.C., Tomkinson A., Giembycz M.A., and Raeburn D. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone. British Journal of Pharmacology 111 (1994) 1081-1088
38. Souness J.E., Aldous D., and Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47 (2000) 127-162
39. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. American Journal of Respiratory and Critical Care Medicine 157 (1998) 351-370
40. Torphy T.J., Barnette M.S., Underwood D.C., Griswold D.E., Christensen S.B., Murdoch R.D., Nieman R.B., and Compton C.H. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulmonary Pharmacology & Therapeutics 12 (1999) 131-135
41. Yokogaki S., Suzuki Y., and Ohashi M. Introduction of a new anti-allergic ophthalmic solution: ibudilast ophtalmic solution (Ketas Eye drops). Japanese Journal of Ocular Pharmacology 16 (2002) 24-28